Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Dennis Durmis MITA names chair of board of directors

RadioMedix scores $2 million contract for Targeted Alpha-emitter therapy Treatment for neuroendocrine tumors

FDA clears United Imaging's total-body PET scanner Creating 3D images of entire human body in 15-30 seconds

FDA clears MIM SurePlan molecular radiotherapy software Can measure the absorbed dose from MRT for individual patients

Rob Beanlands ASNC names president for 2019

Former South African nuclear executives to appeal suspensions in court Involves monthslong shutdown of NTP Radioisotopes medical isotope plant

18F-P3BZA could become the
new gold standard

Researchers find new PET tracer that better detects melanoma than 18F-FDG

by Lauren Dubinsky , Senior Reporter
A research team recently found a new PET tracer that better detects primary and metastatic melanoma than 18F-FDG.

“Melanoma has a poor prognosis,” Zhen Cheng of Stanford University, told HCB News. “Development of specific PET probes to both detect melanoma at its earliest stages and to detect the metastasis of melanoma is critical for improving the survival of patients with malignant melanoma.”

Story Continues Below Advertisement

RaySafe helps you avoid unnecessary radiation

RaySafe solutions are designed to minimize the need for user interaction, bringing unprecedented simplicity & usability to the X-ray room. We're committed to establishing a radiation safety culture wherever technicians & medical staff encounter radiation.

The American Cancer Society estimates that about 96,480 new cases of melanoma will be diagnosed this year. Approximately 7,230 people are expected to die of the disease.

The new 18F-P3BZA tracer targets melanin pigment. It is present in most melanoma lesions and has been shown to shorten overall survival and disease-free survival in patients with metastatic melanoma.

Previous studies have investigated melanin-targeted PET tracers in small animal models, but this is the first time it was tested on humans. This new research demonstrated that 18F-P3BZA is safe and “highly promising” for the clinical diagnosis and staging of melanoma.

The current gold standard for imaging melanoma is 18F-FDG, but it comes with some limitations. It’s not sensitive enough to detect primary melanoma or stage I and II melanomas and it’s a non-specific PET probe that shows accumulations in different tumors from inflamed tissues.

For the new study, the team injected six healthy individuals with 18F-P3BZA and had them undergo whole-body PET/CT scans. They also conducted blood tests at the 10-minute, one-hour, two-hour and four-hour post-injection mark to assess biodistribution, pharmacokinetic and radiation dosimetry.

In addition, five patients with suspected melanomas underwent 18F-P3BZA PET/CT imaging 10 minutes and one hour after injection. All of the study participants also received 18F-FDG PET/CT scans on the third day.

“18F-P3BZA shows selective and rapid uptake in melanoma and metastases, along with a favorable whole-body distribution pattern in vivo,” said Cheng. “It is a highly promising probe that could become a standard for detecting primary and metastatic melanoma.”

But in order for that to happen, the tracer needs to be further evaluated in a large number of patients with primary or metastatic melanoma at multiple research centers.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.